CSP Exam Prep: Growth and Hormonal Disorders

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/21

flashcard set

Earn XP

Description and Tags

Vocabulary practice flashcards covering growth hormone replacement therapy, associated endocrine disorders, diagnostic approaches, drug delivery systems, stability profiles, and GnRH agonist management based on the 2025 NASP CSP Exam Prep Course Study Guide.

22 Terms

1
New cards

Hypopituitarism

A condition characterized by the deficiency of one or more hormones produced by the pituitary gland (such as growth hormone, TSH, LH, FSH, ADH, prolactin, or oxytocin), caused by tumors, trauma, infection, or inflammation.

2
New cards

Panhypopituitarism

A medical condition defined as the complete deficiency of all hormones secreted by the pituitary gland.

3
New cards

Dynamic Hormone Stimulation Testing

A diagnostic procedure utilized when growth hormone (GH\text{GH}) or adrenocorticotropic hormone (ACTH\text{ACTH}) deficiency is suspected, or when morning fasting basal hormone testing yields unclear or non-definitive results.

4
New cards

Noonan Syndrome

An autosomal dominant congenital genetic disorder presenting with distinctive facial features, short stature, heart defects, skeletal malformations, and bleeding problems; confirmed by molecular genetic testing of associated genes including PTPN11, SOS1, RAF1, RIT1, and KRAS.

5
New cards

Prader-Willi Syndrome (PWS)

A complex genetic disorder caused by the loss of function of several genes on chromosome 1515 (via deletion of paternal segment, maternal uniparental disomy, or imprinting), presenting with hypotonia, global developmental delay, hyperphagia, obesity, and hypothalamic hypogonadism.

6
New cards

Turner Syndrome

A chromosomal condition in females caused by the complete or partial absence of the second sex chromosome (45,X\text{45,X}), clinically presenting with short stature, ovarian hypofunction, heart defects (such as coarctation of the aorta), lymphedema, webbed neck, and broad, flat chest.

7
New cards

Idiopathic Short Stature (ISS)

A clinical description defined as height below 22 standard deviations (SD\text{SD}) of the mean for age without an underlying endocrine, metabolic, or systemic etiology; somatropin therapy is indicated only if height is at least 2.25 SD2.25\,\text{SD} below the mean and predicted adult height is below normal range.

8
New cards

Somatropin Mechanism of Action

Recombinant human growth hormone that promotes linear growth, enhances IGF-1-mediated actions in cartilage, bone, and muscle, stimulates protein synthesis, promotes lipolysis and lipid oxidation, antagonizes insulin action, and causes sodium, phosphate, and water retention.

9
New cards

Somatropin Daily Administration Timing

Daily somatotropin administration is most effective when given subcutaneously at night before bedtime to mimic endogenous physiological pulsatile release; injection sites must be rotated to prevent localized lipoatrophy.

10
New cards

Once-Weekly Growth Hormone Formulations

Long-acting recombinant human growth hormone alternatives to daily injections, which include Skytrofa (lonapegsomatropin-tcgd), Sogroya (somapacitan-beco), and Ngenla (somatrogon-ghla), with dosing titrated based on growth response and IGF-1 levels.

11
New cards

Humatrope (somatropin)

A growth hormone brand supplied as 6 mg6\,\text{mg}, 12 mg12\,\text{mg}, and 24 mg24\,\text{mg} cartridges (stable refrigerated for 28 days28\,\text{days} after reconstitution with Humatrope Cartridge Kit) and a 5 mg5\,\text{mg} multidose vial (stable refrigerated for 14 days14\,\text{days}); phased out by manufacturer Lilly by mid-20252025.

12
New cards

Genotropin MiniQuick

A prefilled, premeasured, single-dose, preservative-free somatropin formulation (0.2 to 2 mg0.2\text{ to }2\,\text{mg} in 0.2 mg0.2\,\text{mg} intervals) that can be stored unmixed at room temperature for up to 3 months3\,\text{months} and must be administered immediately or refrigerated for up to 24 hours24\,\text{hours} after reconstitution.

13
New cards

Norditropin FlexPro

A prefilled, premixed, preloaded multidose somatropin pen available in strengths of 5 mg/1.5 mL5\,\text{mg}/1.5\,\text{mL}, 10 mg/1.5 mL10\,\text{mg}/1.5\,\text{mL}, 15 mg/1.5 mL15\,\text{mg}/1.5\,\text{mL}, and 30 mg/3 mL30\,\text{mg}/3\,\text{mL}; once opened, it is stable refrigerated for 28 days28\,\text{days} or at room temperature for up to 21 days21\,\text{days}, and is compatible with the PenMate needle-hiding device.

14
New cards

Nutropin AQ NuSpin

A prefilled, premixed, preloaded multidose somatropin pen formulation (5 mg/2 mL5\,\text{mg}/2\,\text{mL}, 10 mg/2 mL10\,\text{mg}/2\,\text{mL}, and 20 mg/2 mL20\,\text{mg}/2\,\text{mL}) that required refrigeration and use within 28 days28\,\text{days}; all formulations were discontinued in the United States on December 31, 20242024.

15
New cards

Saizen Click.easy and Easypod

An electronic autoinjector system for somatropin where unmixed Click.easy cartridges are stored at room temperature, reconstituted using a disposable kit, loaded into the Easypod smart injector device to track adherence, and stored refrigerated for up to 21 days21\,\text{days}.

16
New cards

Zomacton / Zoma-Jet 10

A somatropin product supplied in 5 mg5\,\text{mg} vials (refrigerated stability of 14 days14\,\text{days}) and 10 mg10\,\text{mg} vials (refrigerated stability of 28 days28\,\text{days}), which can be administered with conventional syringes or the needle-free Zoma-Jet 1010 delivery device.

17
New cards

Slipped Capital Femoral Epiphysis (SCFE)

A recognized orthopedic complication and precaution associated with pediatric growth hormone therapy; warrants immediate evaluation in any child who develops a limp or complains of hip or knee pain.

18
New cards

Central Precocious Puberty (CPP)

Early onset of sexual maturation occurring at an age at least 22 standard deviations younger than the population mean (defined as before age 88 in girls and before age 99 in boys), which can cause early growth plate fusion and shortened adult stature.

19
New cards

Leuprolide Acetate Mechanism of Action

A potent gonadotropin-releasing hormone receptor (GnRHR\text{GnRHR}) agonist that induces an initial surge in LH and FSH secretion, followed by chronic receptor down-regulation, suppression of gonadotropins, and subsequent suppression of gonadal sex steroid production.

20
New cards

Lupron Depot-Ped (1-Month Weight-Based Dosing)

Intramuscular depot leuprolide acetate administered monthly for CPP at 7.5 mg7.5\,\text{mg} for weight ≤25 kg\le 25\,\text{kg}, 11.25 mg11.25\,\text{mg} for weight >25 to 37.5 kg> 25\text{ to }37.5\,\text{kg}, and 15 mg15\,\text{mg} for weight >37.5 kg> 37.5\,\text{kg}.

21
New cards

Fensolvi (leuprolide acetate)

A subcutaneous GnRH agonist suspension formulation supplied in a two-syringe kit (Syringe A with ATRIGEL diluent and Syringe B with 45 mg45\,\text{mg} lyophilized powder) administered by a healthcare professional once every 6 months6\,\text{months} for central precocious puberty.

22
New cards

Insulin-Like Growth Factor 1 (IGF-1) Monitoring

A laboratory parameter monitored at baseline, every 3 to 6 months3\text{ to }6\,\text{months}, and following dose adjustments to titrate growth hormone replacement therapy and confirm biological responsiveness.